CD274 and neoplasm: Based on the abovementioned criteria, the inclusion of 750 patients who are followed for at least 1 year is needed to yield (a) 90% power to declare non-inferiority according to the first criterion–assuming an equal true 1-year OS rate on both treatment regimens of 70%–and (b) 91% power to find non-inferiority when the percentage of patients with a tumour PD-L1 expression ≥50% is lower than 75% according to the second criterion.